Betuvax has raised ₽100 million in venture capital investment

Betuvax, part of the Artgen Biotech group, has raised about ₽100 million in venture capital investment in a private placement. Funds will be used to conduct preclinical and clinical studies of the drug against cat allergy, as well as to develop vaccines against human papillomavirus and rotavirus.